GlaxoSmithKline Consumer Healthcare (Overseas) Limited
GlaxoSmithKline Consumer Healthcare (Overseas) Limited, commonly referred to as GSK Consumer Healthcare, is a leading player in the global consumer health industry, headquartered in Great Britain. Founded in 2019 as a spin-off from GlaxoSmithKline plc, the company has quickly established itself in key operational regions, including Europe, North America, and Asia. Specialising in over-the-counter products, GSK Consumer Healthcare offers a diverse portfolio that includes oral health, pain relief, respiratory health, and dietary supplements. Their commitment to innovation and quality sets their products apart in a competitive market. With a strong market position, GSK Consumer Healthcare is recognised for its trusted brands, such as Sensodyne and Panadol, which have achieved notable success and consumer loyalty worldwide.
DitchCarbon Score
How does GlaxoSmithKline Consumer Healthcare (Overseas) Limited's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Real Estate Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
GlaxoSmithKline Consumer Healthcare (Overseas) Limited's score of 77 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
GlaxoSmithKline Consumer Healthcare (Overseas) Limited, headquartered in Great Britain, currently does not report specific carbon emissions data, as indicated by the absence of emissions figures. The company is a current subsidiary of Haleon plc, which cascades its climate commitments and initiatives down to its subsidiaries. Haleon plc has set ambitious climate targets, including commitments to reduce carbon emissions across its operations. These initiatives are part of a broader strategy to achieve sustainability and align with industry standards. The emissions data and reduction targets from Haleon plc are relevant for understanding the environmental impact of GlaxoSmithKline Consumer Healthcare (Overseas) Limited. As a subsidiary, GlaxoSmithKline Consumer Healthcare (Overseas) Limited adheres to the climate pledges and reduction initiatives established by Haleon plc, which include participation in the Science Based Targets initiative (SBTi) and the Carbon Disclosure Project (CDP). These commitments reflect a proactive approach to managing climate risks and reducing carbon footprints across the supply chain. In summary, while specific emissions data for GlaxoSmithKline Consumer Healthcare (Overseas) Limited is not available, the company is aligned with the climate strategies of its parent organization, Haleon plc, which is focused on significant reductions in carbon emissions and sustainability efforts.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Scope 1 | 59,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 37,000,000 | 00,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 3 | - | - | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
GlaxoSmithKline Consumer Healthcare (Overseas) Limited is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
